INDEPENDENT POLICY ANALYSIS · ECONOMIC DETERMINANTS OF HEALTH · HEALTH INNOVATION · UK INDUSTRIAL STRATEGY

The question is not simply why Britain has fewer technology giants than America. It is why a country capable of producing valuable knowledge sometimes struggles to retain the economic, industrial and public benefits of that knowledge.

This question belongs in a serious public-health discussion.

Health is influenced by more than clinical services. Employment, household security, education, working conditions, local opportunity and the distribution of economic resources all shape the circumstances in which people live.

The Primary Health Awareness Trust (PHAT) approaches this subject as an independent question of public value: can Britain turn its scientific and entrepreneurial capabilities into sustainable prosperity, stronger health innovation and benefits that reach the wider population?

This is not an argument that every country needs a Google or Microsoft, nor that corporate size automatically improves health. It is an investigation into the institutions that help ideas become productive businesses — and whether the resulting benefits are shared fairly and used effectively.

1. The difference between inventing the future and owning its value

Global technology businesses do more than sell products. They create platforms, infrastructure, intellectual property and networks that other businesses depend upon. Their influence can extend into cloud computing, artificial intelligence, advertising, communications, healthcare data and the software used throughout the economy.

Britain has produced internationally important technology businesses and research. Arm, founded in Cambridge, developed processor architecture used across much of the modern electronics industry. British-founded AI research company DeepMind became part of Google. These examples illustrate both the strength of British innovation and the international ownership structures through which its value can be developed.

There is an important distinction here. Research conducted in Britain can benefit humanity even when a company is owned abroad. International investment can provide capital, distribution and access to markets that would otherwise be unavailable. Foreign ownership is not inherently a failure.

The strategic question is whether Britain retains enough of the high-value activity: research and development, skilled employment, decision-making, manufacturing, intellectual property, tax receipts and the capacity to develop the next generation of products.

A country can be successful at scientific discovery while capturing too little of the later commercial value. The same distinction matters in healthcare, where an effective discovery must still be tested, manufactured, approved, purchased and incorporated into clinical practice before patients can benefit.

2. London has businesses and capital. Why is scaling still difficult?

London is not a business desert. It is one of Britain’s most concentrated centres of finance, professional services, technology investment and entrepreneurship. The question is whether the system surrounding its businesses makes it sufficiently easy to grow from a promising company into a global enterprise.

The British Business Bank’s Small Business Equity Tracker 2025 reported that UK smaller-business equity investment fell by 2.5% to £10.8 billion in 2024, while the number of deals fell by 15.1%. London accounted for 61% of investment and 47% of deals that year.

Its subsequent 2026 report on the 2025 market found that smaller-business equity investment declined by 4% to £12.3 billion. AI companies attracted 44% of the investment, demonstrating both the importance of this sector and the concentration of funding around particular opportunities.

These figures do not prove that Britain cannot build large companies. Nor do they establish that London’s entire investment system is failing. They do raise questions about the depth, distribution and continuity of growth finance.

The scale-up funding gap

Early-stage capital helps an entrepreneur test a product and assemble a team. A company seeking to compete internationally may subsequently need much larger sums for regulatory approval, specialist staff, computing infrastructure, manufacturing, overseas expansion and acquisitions.

That transition is especially difficult in industries where research is expensive and returns may take years to arrive. Biotechnology, advanced medical devices, semiconductors and industrial technologies can require substantial investment before revenue becomes predictable.

The British Business Bank has repeatedly identified differences between UK and US venture investment, including a UK investment gap relative to the size of the economy. Its research also identifies particular challenges in research-intensive industries.

For policymakers, the question should therefore extend beyond how many companies are founded. It should include how many survive, reach international markets, increase productivity, retain important capabilities in Britain and become large, durable employers.

3. Britain’s investment paradox: financial wealth versus productive capacity

In June 2026, the House of Commons Business and Trade Committee highlighted a mismatch between the UK’s financial resources and the financing available to growing businesses. Its report, Investing in the UK Economy, pointed to substantial pension assets, cash savings and businesses unable to obtain finance.

The committee argued that institutional reform could help unlock substantially more investment. Its headline estimates are policy analysis and should be read as such, rather than as guaranteed economic outcomes.

Nevertheless, the underlying question deserves attention: why can a country with deep financial markets still struggle to direct sufficient long-term funding towards productive domestic businesses?

• Risk and time horizons: pension trustees, investment managers and other institutions must consider their legal duties, liquidity requirements, costs and investment risks. Long-term growth companies may not fit every portfolio.
• Market incentives: financing established assets can be easier to assess than funding a company with uncertain revenue and expensive research requirements.
• Exit routes: founders and investors need credible ways to realise returns. A limited pool of domestic growth investors or public-market buyers can make foreign acquisition more attractive.
• Fragmentation: research institutions, investors, manufacturers, regulators and major customers may operate with different priorities, timetables and incentives.

None of these factors requires a hidden plan to prevent British success. A system can produce poor collective outcomes even when individual decisions appear rational.

That is a more useful question for government than simply asking whether Britain is pro-business or anti-business. Which incentives, rules and institutional arrangements are helping capital reach productive opportunities, and which are impeding it?

4. Why PHAT should care: the economic infrastructure of health

PHAT’s interest is not the pursuit of corporate prestige. It is the connection between economic institutions and the conditions required for a healthier population.

The relationship needs to be described carefully. A large company is not automatically a public-health benefit, and economic growth does not guarantee that every household becomes healthier. The mechanisms linking economic activity to health must be examined rather than assumed.

Household security and the social determinants of health

Secure, fairly paid employment can support housing stability, access to essentials, social participation and a greater ability to manage financial shocks. Conversely, insecure work, prolonged unemployment and financial strain can undermine wellbeing.

These are pathways through which economic conditions may affect health. The distribution of jobs, pay, working conditions and opportunities matters as much as headline growth figures.

A successful technology cluster may create highly paid jobs while leaving many local residents unable to access them. Policymakers should therefore examine who gains employment, which skills are required, whether local people can access training and how growth affects housing and transport pressures.

Health innovation: from laboratory discovery to patient benefit

Britain’s life-sciences sector demonstrates the connection particularly clearly. The government’s Life Sciences Sector Plan recognises that the UK has strong scientific capabilities but has struggled with commercialisation, access to later-stage capital and the adoption of innovation.

The plan also acknowledges that policy ideas have not always translated into effective delivery. It connects industrial development with the NHS, research, clinical trials, manufacturing and patient access.

This matters because a discovery has limited practical value to a patient if it cannot be developed into a safe, effective, affordable and accessible intervention.

For example, the pathway for a new diagnostic technology may involve research, clinical validation, regulatory assessment, manufacturing capacity, procurement decisions, staff training and integration into existing services. Failure at any stage can delay adoption.

Commercial success is not the sole measure of health value. Some valuable interventions may have limited commercial potential, especially when they serve small populations or disadvantaged communities. Public funding, research charities and responsible procurement can therefore remain essential.

5. What happens when valuable research cannot scale?

Consider a hypothetical British company developing an affordable diagnostic test. University researchers establish that the technology is promising. Early investment supports a prototype and initial validation.

The company now needs additional finance, manufacturing expertise, regulatory support and access to clinical settings. NHS procurement can be complex. Larger overseas markets may offer more immediate commercial opportunities. A foreign investor offers the capital and distribution network required to expand.

The company accepts the investment. The product may go on to benefit patients internationally, including British patients. That is a potentially positive outcome.

But policymakers should still ask what happens to the manufacturing, skilled jobs, intellectual property, tax contribution and future research activity. Could more of the value have been retained in Britain without compromising patient access or the company’s ability to compete?

This example is illustrative, not a claim about a particular company. It identifies the questions that a serious evaluation should answer.

The objective cannot be to prevent all overseas investment or acquisition. It should be to make Britain a sufficiently attractive place to develop, finance and expand successful businesses while protecting the public interest.

6. Is Britain structurally favouring established wealth?

This is a legitimate hypothesis, but it requires more precise evidence than political slogans can provide.

Existing assets, established firms and familiar investment categories can have advantages over new businesses whose potential is difficult to measure. Property, mature financial assets and established companies may be easier for investors to understand than an early-stage medical technology or a research-intensive manufacturer.

That does not establish that policymakers deliberately suppress entrepreneurship. Nor does it mean that investing in property or established companies is inherently unproductive.

Testing that proposition would require evidence on investment flows, business survival, capital costs, ownership changes, company relocation, research expenditure, productivity and the distribution of resulting gains.

It would also require comparisons with other economies adjusted for sector mix, market size, risk, taxation and the different roles played by public and private finance.

7. The policy test: what should government measure?

Britain already has policies intended to improve innovation, investment and life sciences. The question is whether those policies deliver measurable results, for whom, and at what public cost.

PHAT proposes a public-value framework that could help policymakers evaluate the relationship between business development and health.

8. A practical agenda for London and the UK

PHAT recommends that government, local authorities, research institutions, the NHS and investment organisations consider the following priorities.

1. Connect research with growth finance.
   Strengthen routes from early-stage research to later-stage investment, particularly for capital-intensive health, biotechnology, advanced manufacturing and diagnostic technologies.
2. Make public procurement a route to responsible adoption.
   Help innovative suppliers navigate transparent procurement pathways while maintaining clinical safety, value for money and fair competition.
3. Improve the commercialisation of public research.
   Evaluate the incentives, costs and contractual arrangements that determine whether university discoveries can become sustainable businesses. Protect academic independence and the public interest in publicly funded research.
4. Develop skills and manufacturing capacity.
   Support the workforce, facilities and supply chains required to manufacture and deploy important technologies, not merely design them.
5. Make growth more inclusive.
   Connect technology clusters with local education, training and employment opportunities. Assess the distribution of benefits instead of treating investment totals as a complete measure of success.
6. Publish outcomes consistently.
   Establish a transparent reporting framework that follows companies, public funding, innovation adoption and health outcomes over time, subject to appropriate confidentiality and data-protection safeguards.

These measures should complement existing industrial and health strategies rather than create another disconnected programme. The value lies in connecting objectives that are often evaluated separately.

9. The questions government should be prepared to answer

• How much publicly funded British research becomes commercially successful products, and how long does that process take?
• Which sectors face the largest gaps in growth finance, and what evidence identifies the causes?
• What proportion of publicly supported health innovations reaches routine clinical use, and how quickly?
• How are the economic and health benefits distributed between regions and population groups?
• When a promising company moves its ownership, manufacturing or research overseas, what were the contributing factors and could policy realistically have changed the outcome?
• Which interventions deliver additional investment and public value that would not otherwise have occurred?

These questions should be addressed through transparent data, independent evaluation and engagement with patients, researchers, entrepreneurs, workers and investors.

10. The conclusion: growth should serve the public

Britain does not lack scientific talent, entrepreneurial ambition or financial expertise. Its challenge is to make these strengths work together more effectively.

London’s global financial role is an asset. International investment can help British companies expand. Global partnerships can accelerate scientific progress. But those advantages should not distract from the question of whether Britain can develop the institutions, markets and capabilities required to turn its knowledge into enduring productive capacity.

The public-health relevance is direct enough to deserve serious investigation, but it must not be overstated. Stronger businesses do not automatically produce healthier populations. The connection depends on the quality of employment, the distribution of prosperity, the responsible use of public resources and whether innovation actually improves people’s lives.

For PHAT, this is the central issue: economic policy, research policy and health policy should be evaluated not only by what they promise, but by what they deliver to the public.

Sources and further reading

The following official sources support the economic, industrial and health-policy context discussed above. The proposed PHAT framework is an independent policy proposal, not an official government recommendation.

1. British Business Bank — Small Business Equity Tracker 2025
   UK equity investment trends, deal activity, regional investment and the scale-up financing environment.
2. British Business Bank — Small Business Equity Tracker 2026 announcement
   Investment trends reported for 2025.
3. House of Commons Business and Trade Committee — Investing in the UK Economy
   Parliamentary analysis of investment institutions and business finance.
4. UK Government — Life Sciences Sector Plan
   Research, commercialisation, growth capital, manufacturing and health-system adoption.
5. Office for National Statistics — Business Demography, UK: 2024
   Business births, deaths, survival and high-growth enterprise statistics.
6. UK Government — High-growth firms
   Analysis of high-growth businesses and their relationship with productivity.

---

Editorial note: This article provides policy analysis and public-health commentary. It does not provide investment, medical or legal advice. Statistics and policy positions should be checked against the latest source publications before republication or use in formal submissions.